The largest stock exchange in India, the National Stock Exchange (NSE), has started a massive ₹380-crore project to build a bone marrow transplant (BMT) center and an 11-story multispecialty hospital block at the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), which is part of the Tata Memorial Centre (TMC) in Navi Mumbai. The project, which was authorized by the NSE board in March 2023, is a major step in the NSE Foundation’s corporate social responsibility (CSR) effort to close important gaps in the nation’s cancer treatment infrastructure. This facility will be built by Larsen & Toubro and will have a built-up area of 2.4 lakh square feet. It is expected to be operational by July 2027.
Facility Features and Capacity:
The new NSE multispecialty hospital block will be the largest of its kind in India, housing a state-of-the-art 60-bed Bone Marrow Transplant (BMT) centre, projected to be among the largest in South Asia. The hospital is designed to cater to around 1.3 lakh outpatient department (OPD) visits annually and conduct over 600 lifesaving BMT procedures every year. Beyond cancer treatment, the hospital will offer super-specialty services targeting comorbidities such as cardiac, pulmonary, neurological, renal, and gastroenterological complications frequently experienced by cancer patients, reducing the need for patients to seek care elsewhere. This comprehensive approach aims to deliver affordable, high-quality care to thousands of patients, many of whom come from financially disadvantaged backgrounds.
Significance for India’s Cancer Care Landscape:
The availability of specialist and reasonably priced therapies, such as bone marrow transplants, is still a major concern given the surge in cancer incidence across the country. Thousands of patients are currently waiting for BMT operations, which are a complicated and expensive treatment that is frequently out of reach in private hospitals (sometimes costing more than ₹40 lakh) and even expensive in public institutions. By providing discounted, and frequently free, access to cutting-edge cancer treatments, NSE’s collaboration with Tata Memorial Centre seeks to close this disparity. The new institution will improve Navi Mumbai’s healthcare system and establish it as a center for innovative cancer research and treatment.
Statements from Leadership and Project Outlook
Ashishkumar Chauhan, Managing Director and CEO of NSE, expressed pride in supporting healthcare through this transformative initiative. He emphasized NSE’s core vision of societal impact and highlighted the project’s lasting influence on thousands of patients’ lives every year. Dr. Sudeep Gupta, Director of Tata Memorial Centre, highlighted the critical nature of this facility in addressing complex comorbid conditions in cancer patients and highlighted the facility’s role in fulfilling growing treatment demands. The project’s final environmental clearance was obtained in September 2025, with the construction commencement certificate following in October 2025, marking swift progress aligned with the goal to operationalize the facility by mid-2027.
An important development in the country’s fight against cancer is the ₹380-crore investment made by NSE to construct India’s largest BMT center and multispecialty cancer hospital on the ACTREC campus of Tata Memorial Centre. This hospital has the potential to improve access to treatment, expedite care for complicated situations, and establish itself as a symbol of hope and health equity in India.
